R&D News | pharmaphorum

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

Call goes out for simpler clinical trial regulation in UK

Clinical trials are strictly regulated to ensure patient safety, but the current framework in the UK is stifling early-phase clinical research, making it harder to advance novel therapies t

News

Lexeo therapy gives hope to Friedreich's ataxia patients

An experimental gene therapy developed by Lexeo Therapeutics has shown early promise in treating one of the most serious complications of the rare neurodegenerative disorder, Friedreich's a

News

UK’s Destiny Pharma hops on the AIM delisting train

Destiny Pharma has joined a growing list of UK biotechs seeking to delist from the Alternative Investments Market (AIM) and return to private ownership.

News

Ozempic’s latest health benefit may be cutting dementia risk

Another week, and another study has emerged pointing to a way that GLP-1 receptor agonists may benefit human health.

News

Immutep mulls filings for LAG-3 drug after new readout

Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patient

Novo leads $100m financing for Alzheimer's player Asceneuron

Call goes out for simpler clinical trial regulation in UK

Lexeo therapy gives hope to Friedreich's ataxia patients

UK’s Destiny Pharma hops on the AIM delisting train

Ozempic’s latest health benefit may be cutting dementia risk

Immutep mulls filings for LAG-3 drug after new readout

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks